CBS 2019
CBSMD教育中心
中 文

光学相关断层扫描

Abstract

Recommended Article

Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: the ESTROFA OCT BVS vs. BP-DES study Volumetric characterization of human coronary calcification by frequency-domain optical coherence tomography The Relation Between Optical Coherence Tomography-Detected Layered Pattern and Acute Side Branch Occlusion After Provisional Stenting of Coronary Bifurcation Lesions Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study Optical coherence tomography versus intravascular ultrasound to evaluate coronary artery disease and percutaneous coronary intervention Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study Coronary Atherosclerosis T1-Weighed Characterization With Integrated Anatomical Reference: Comparison With High-Risk Plaque Features Detected by Invasive Coronary Imaging Optical Coherence Tomography-Guided Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Prospective Propensity-Matched Cohort of the Thrombectomy Versus Percutaneous Coronary Intervention Alone Trial
|<< 1 2 3 4 5 6 7 8 >>|

JOURNAL：MedPage Today Article Link

FDA Rejects Canakinumab in CVD Prevention

Nicole Lou, Contributing Writer, MedPage Today Keywords: cantos


It's official: the FDA declined to approve canakinumab (Ilaris) for cardiovascular risk reduction on the strength of data from the CANTOS trial, according to drugmaker Novartis.


"Based on the correspondence, the CANTOS data would not support labeling for the use of canakinumab as a targeted therapy for those patients with cardiovascular disease who achieved a reduction of hsCRP [high-sensitivity C-reactive protein] below the 2 mg/L target," the company said in a statement. Initially, the company had buried the announcement in its quarterly financial report.

The $200,000-a-year interleukin-1β inhibitor had been approved in 2013 for certain rare inflammatory disorders.

In 2017, CANTOS results showed the drug reduced cardiovascular events by 15% among more than 10,000 patients with a history of myocardial infarction followed for a median of 3.7 years. This was seen as validation of the inflammation hypothesis in heart disease, though the effect was modest and the drug made no noticeable dent in all-cause mortality.

That combination of small benefit and high price raised questions about Novartis's ability to actually sell the drug for this indication, but evidently the company thought it was worth the effort.

Investigators also found a decreased risk of lung cancer among canakinumab recipients. For that reason, Novartis said its phase III canakinumab trials in non-small cell lung cancer would continue and the first study would be completed in 2022.

Notably, the potential benefits of canakinumab come with an important trade-off: the drug was associated with an increased risk of fatal infection in CANTOS.
>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top